Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Securities (2022 - 2023)

BioRestorative Therapies (BRTX) has disclosed Securities for 1 consecutive years, with $13.0 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Securities changed N/A year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Dec 2022, changed N/A, and an annual FY2022 reading of $13.0 million, changed N/A over the prior year.
  • Securities was $13.0 million for Q4 2022 at BioRestorative Therapies.
  • Across five years, Securities topped out at $13.0 million in Q4 2022 and bottomed at $13.0 million in Q4 2022.